- Home
- PWR vs GEHC Comparison
PWR vs GEHC Comparison
Compare PWR & GEHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PWR
- GEHC
- Stock Information
- Founded
- PWR 1997
- GEHC 1892
- Country
- PWR United States
- GEHC United States
- Employees
- PWR N/A
- GEHC N/A
- Industry
- PWR Engineering & Construction
- GEHC Computer Software: Prepackaged Software
- Sector
- PWR Industrials
- GEHC Technology
- Exchange
- PWR Nasdaq
- GEHC Nasdaq
- Market Cap
- PWR N/A
- GEHC 37.5B
- IPO Year
- PWR 1998
- GEHC N/A
- Fundamental
- Price
- PWR $257.90
- GEHC $79.57
- Analyst Decision
- PWR Strong Buy
- GEHC Buy
- Analyst Count
- PWR 19
- GEHC 12
- Target Price
- PWR $325.94
- GEHC $98.75
- AVG Volume (30 Days)
- PWR 1.6M
- GEHC 3.4M
- Earning Date
- PWR 05-01-2025
- GEHC 04-29-2025
- Dividend Yield
- PWR 0.16%
- GEHC 0.18%
- EPS Growth
- PWR 20.60
- GEHC 43.17
- EPS
- PWR 6.03
- GEHC 4.34
- Revenue
- PWR $23,672,795,000.00
- GEHC $19,672,000,000.00
- Revenue This Year
- PWR $14.68
- GEHC $3.77
- Revenue Next Year
- PWR $9.71
- GEHC $4.72
- P/E Ratio
- PWR $42.77
- GEHC $18.33
- Revenue Growth
- PWR 13.36
- GEHC 0.61
- 52 Week Low
- PWR $227.11
- GEHC $74.51
- 52 Week High
- PWR $365.88
- GEHC $94.80
- Technical
- Relative Strength Index (RSI)
- PWR 44.53
- GEHC 34.07
- Support Level
- PWR $244.70
- GEHC $79.20
- Resistance Level
- PWR $279.75
- GEHC $82.89
- Average True Range (ATR)
- PWR 8.77
- GEHC 1.64
- MACD
- PWR 0.89
- GEHC -0.15
- Stochastic Oscillator
- PWR 41.75
- GEHC 7.52
About GEHC GE HealthCare Technologies Inc.
GE HealthCare Technologies is a leading medical technology firm with leading market share in imaging and ultrasound equipment. The company reports four major segments: imaging (45% of revenue), advanced visualization solutions (26%), patient care solutions (16%), and pharmaceutical diagnostics (13%). The company's sales are geographically diverse, with the United States, EMEA, China, and the rest of the world accounting for 46%, 26%, 12%, and 17% respectively. We estimate approximately half of its revenue is recurring, which consists of servicing (about one third of revenue), pharmaceutical diagnostics (about 10%-15%), and digital solutions (just over 5%).